NCT04164966Active, not recruitingNot Applicable
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes
AdventHealth Translational Research Institute1 site in 1 country28 target enrollmentStarted: November 27, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples
Study Overview
Brief Summary
The purpose of this study is to measure the levels of certain substances (biomarkers) in the body that may indicate the triggers of Type 1 Diabetes, to find a better way to diagnose the disease, as well as to follow its progression.
Study Design
- Study Type
- Observational
- Observational Model
- Other
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 12 Years to 18 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Type 1 Diabetes (T1D)
- •Age 12-18 years inclusive
- •Diagnosis of T1D according to American Diabetes Association (ADA) criteria with an acute onset and presence of islet associated autoantibody by history.
- •T1D duration of ≤ 3 months from the diagnosis
- •Healthy Normal Volunteers (HNV)
- •Age 12-18 years inclusive
- •No personal history of diabetes according to ADA criteria
- •No history of T1D or insulin treated diabetes in first degree relatives (FDR)
Exclusion Criteria
- •Acute or chronic medical conditions or medication that would contraindicate the participation in the research testing or could potentially affect metabolic and immune function including, but not limited to:
- •History of type 2 diabetes
- •Suspicion of non-type 1 diabetes (e.g. maturity onset diabetes of the young or secondary diabetes)
- •History of thyroid dysfunction in which the participant has not been on a stable dose (at least 6 weeks prior to enrollment) of thyroid replacement medication or antithyroid drugs.
- •History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable).
- •History of organ transplant
- •History of HIV, active Hepatitis B or C, or Tuberculosis
- •Pregnancy, lactation or 6 months postpartum from the scheduled date of collection
- •Psychiatric disease prohibiting adherence to study protocol
- •Use of oral or injectable anti-hyperglycemic agents: metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, acarbose, GLP-1 analogs.
- •Use of any other medications known to influence glucose, fat and/or energy metabolism within the last 3 months (e.g., growth hormone therapy, glucocorticoids [steroids], prescribed medications for weight loss, etc.)
- •Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study visits
Outcomes
Primary Outcomes
Characterization of circulating β cell-specific exosomes in children with T1D and healthy normal controls using baseline samples
Time Frame: 2-3 hours
Measure will be the number (concentration) of circulating beta-cell specific exosomes. If the characterization of circulating beta-cell specific exosomes is not feasible in children with T1D due to the potentially limited low input amount of this type of exosomes in the circulation of these participants, an alternative analysis will be implemented.
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting PrognosisPlaque RuptureAcute Coronary SyndromesNCT06763835Xuebo Liu301
Recruiting
Not Applicable
Development of biological markers for early diagnosis and target treatment of carcinogenic processes of digestive cancer (pancreatic cancer, biliary tract cancer, gallbladder cancer, etc.)KCT0006268Yonsei University Health System, Gangnam Severance Hospital3,000
Completed
Not Applicable
Research of Biomarkers in Duchenne Muscular Dystrophy PatientsDuchenne Muscular Dystrophy (DMD)NCT01380964Genethon220
Completed
Not Applicable
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant RecipientsLiver Transplant RecipientsLiver TransplantationNCT01672164National Institute of Allergy and Infectious Diseases (NIAID)202
Recruiting
Not Applicable
Investigation of biomarkers for diagnosis and treatment of pulmonary hypertension.Pulmonary hypertensionJPRN-UMIN000032888Juntendo University50